About prothena corp. plc - PRTA
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
PRTA At a Glance
Prothena Corp. Plc
77 Sir John Rogersons Quay
Dublin, Dublin 2
| Phone | 353-1-236-2500 | Revenue | 9.68M | |
| Industry | Biotechnology | Net Income | -244,092,000.00 | |
| Sector | Health Technology | Employees | 67 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PRTA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 53.084 |
| Price to Book Ratio | 1.833 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.188 |
| Enterprise Value to Sales | 22.192 |
| Total Debt to Enterprise Value | 0.039 |
PRTA Efficiency
| Revenue/Employee | 144,537.313 |
| Income Per Employee | -3,643,164.179 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.022 |
PRTA Liquidity
| Current Ratio | 7.717 |
| Quick Ratio | 7.717 |
| Cash Ratio | 7.53 |
PRTA Profitability
| Gross Margin | 61.772 |
| Operating Margin | -1,905.824 |
| Pretax Margin | -2,073.823 |
| Net Margin | -2,520.57 |
| Return on Assets | -55.862 |
| Return on Equity | -63.615 |
| Return on Total Capital | -84.506 |
| Return on Invested Capital | -62.498 |
PRTA Capital Structure
| Total Debt to Total Equity | 2.985 |
| Total Debt to Total Capital | 2.899 |
| Total Debt to Total Assets | 2.562 |
| Long-Term Debt to Equity | 1.956 |
| Long-Term Debt to Total Capital | 1.90 |